

\*張獻崑醫師

所有發表期刊論文

1. **Chang HK**, Wang CH, Lai GM et al. (1992): Prognosis of thymic Carcinoma: analysis of 16 cases. *J Formosan Med Assoc* 91: 764-9.
2. Lai GM, **Chang HK**, Wang CH. (1994): Salvage chemotherapy using mitoxantrone and 5-fluorouracil plus leucovorin for heavily pretreated metastatic breast cancer patients. *J Chinese Oncol Soc* 10: 2-11.
3. Lin YC, **Chang HK**, Sun CF, Shih LY. (1995): Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary--- a case report. *Southern Med J* 88(6): 683-7.
4. Wang HM, Wang CH, Chen JS, **Chang HK** et al. (1995): Predictive factors of cisplatin and 5-fluorouracil as neoadjuvant chemotherapy response in head and neck squamous cell carcinoma. *J Formosan Med Assoc* 94: 87-94.
5. Liaw CC, Wang CH, Huang JS, **Chang HK** et al. (1997): Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. *Acta Oncologica* 36(2): 159-64.
6. Liaw CC, Chuang CK, Chen JS, **Chang HK**. (1997): Gastric cancer with obstructive uropathy: clinical experience with 17 cases. *Chang Gung Med J* 20: 286-92.
7. Liaw CC, Chen JS, Wang CH, **Chang HK**, Huang JS. (1998); Tumor fever in patients with nasopharyngeal carcinoma: clinical experience of 67 patients. *Am J Clin Oncol* 21:422-425.
8. Liaw CC, Wang HM, Wang CH, **Chang HK** et al. (1999): Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. *Anti-Cancer Drugs* 10:275-281.
9. Chen PY, See LC, Wang CH, Lai YH, **Chang HK**, Chen ML (1999): The impact of pain on the anxiety and depression of cancer patients. *Formosan J Med* 3:373-82.
10. Wan YL, Cheung YC, Hsueh S, Lui KW, **Chang HK** et al. (1999): Automated Stereotaxic core needle biopsy of breast lesions. *The Chinese J. Radiology* 24(3):95-99
11. Liaw CC, Wang CH, **Chang HK** et al. (2000): Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: A crossover study of triple 8-mg dose of ondansetron. *Am J Clin Oncol* 23(3):253-257

12. Liaw CC, Wang CH, **Chang HK** et al. (2000): Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone. *Chang Gung Med J* 23:413-9.
13. Lin YC, **Chang HK**, Wang CH et al.(2000): Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracycline and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. *Anti-Cancer Drugs* 11:617-621.
14. Liaw CC, Wang CH, **Chang HK** et al.(2001): Gender discrepancy observed between chemotherapy-induced emesis and hiccup. *Supportive Care Cancer* 9:435-441.
15. Lin YC, Chen JS, Wang CH, Wang HM, **Chang HK** et al.(2001): Weekly High-dose 5-Fluorouracil, Leucovorin and bimonthly Cisplatin in patients with advanced gastric cancer. *Jpn J Clin Oncol* 31(12):605-609.
16. Liaw CC, **Chang HK**, Liaw CT et al (2003): Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. *Am J Clin Oncol (CCT)* 26 (1): 12-15.
17. Cheung YC, Chen SC, Su MY, **Chang HK** et al. (2003): Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. *Breast Cancer Research and Treatment* 78:51-58.
18. Chen ML, **Chang HK** (2004): Physical symptom profiles of depressed and nondepressed patients with cancer. *Palliative Medicine* 18:712-718.
19. Chen SC, **Chang HK**, Lin YC et al. (2005): Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. *Onkologie* 28:339-344.
20. Lin YC, Chen SC, **Chang HK** et al.(2005): Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) chemotherapy. *Jpn J Clin Oncol* 35(9):514-519.
21. Liaw CC, Wang CH, **Chang HK** et al. (2005): Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting. *J Pain Symptom Manage* 30: 359-366.
22. Chen SC, **Chang HK**, Lin YC et al. (2006): Prognosis of breast cancer after supraclavicular lymph node metastasis: not a distant metastasis. *Annals of Surgical Oncology* 13:1457-1465.
23. Lin YC, **Chang HK**, Chen JS et al. (2007): A phase II Randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final

- analysis. *Jpn J Clin Oncol.* 37(1):23-9.
24. Lin YC, **Chang HK**, Shen WC et al. (2007): An Open-labeled phase II trial of docetaxel in combination with cisplatin as a first-line cytotoxic therapy for anthracycline-naïve patients with metastatic breast cancer. *Anticancer Drugs.* 18(10):1213-9.
  25. Lu CH, Lin YC, **Chang HK**. (2007): Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital. *Chang Gung Med J.* 30(1):33-40.
  26. Liaw CC, Chen JS, **Chang HK** et al. (2008): Symptoms and signs of port-related infections in oncology patients related to the offending pathogens. *Int J Clin Pract.* 62(8):1193-8.
  27. Chen SC, **Chang HK**, Lin YC et al. (2008): High pathologic complete response in HER2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. *Jpn J Clin Oncol.* 38(2):99-105.
  28. Chao YK, Chan SC, **Chang HK** et al. (2009): Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. *Eur J Surg Oncol.* 35(3):289-94.
  29. Chao YK, Chan SC, **Chang HK** et al. (2009): Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. *Ann Surg.* 249(3):392-6.
  30. Hsu HC, **Chang HK**, Lin YC et al. (2009): The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. *Chang Gung Med J.* 32(1):33-41.
  31. Chuang WY, Yeh CJ, **Chang HK** et al. (2009): Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. *Histol Histopathol.* 24(8):1021-7.
  32. Chang H, Liaw CC, **Chang HK**. (2009): Therapy-related acute myeloid leukemia after concurrent chemoradiotherapy for esophageal cancer: report of two cases. *Tumori.* 95(3):371-3.
  33. Nan YY, Liu YC, **Chang HK** et al. (2010): Angiosarcoma in the aortic arch presented as repeat strokes. *J Thorac Cardiovasc Surg.* 139(3):e40-2.
  34. Chao YK, Wu YC, **Chang HK** et al. (2010): Distant nodal metastases from intrathoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after chemoradiotherapy. *J Surg Oncol.* 102(2):158-62.
  35. Liaw CC, Huang JS, **Chang HK** et al. (2010): Using vital sign flow sheets can

- help to identify neoplastic fever and other possible causes in oncology patients: a retrospective observational study. *J Pain Symptom Manage.* 40(2):256-65.
36. Kuo CJ, Lin TN, **Chang HK** et al. (2010): Clinical manifestation of esophageal carcinosarcoma: a Taiwan experience. *Dis Esophagus.* 23(2):122-7.
  37. Chang H, Liaw CC, **Chang HK**. (2011): Earlier and commoner: therapy-related leukemia after concurrent chemoradiotherapy for esophageal cancer. *Eur J Haematol.* 86(4): 356.
  38. Yeh CJ, Chuang WY, **Chang HK** et al. (2011): High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. *Virchows Arch.* 458(2):171-8.
  39. Su PJ, Chen JS, **Chang HK** et al. (2011): Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma. *Chang Gung Med J.* 34(5):478-86.
  40. Hsu CL, Chang KP, **Chang HK** et al. (2011): Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. *Head Neck.* 34(8):1064-70.
  41. Chao YK, Yeh CJ, **Chang HK** et al. (2011): Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. *Ann Surg Oncol.* 18(2):529-34.
  42. Chen WH, Chao YK, **Chang HK** et al. (2012): Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma. *Dis Esophagus.* 25(3):250-5.
  43. Shen SC, Liao CH, **Chang HK** et al. (2012): Favorable outcome of secondary axillary dissection in breast cancer patients with axillary nodal relapse. *Ann Surg Oncol.* 19(4):1122-8.
  44. Chao YK, Liu HP, **Chang HK** et al. (2012): Impact of the number of lymph nodes sampled on outcome in ypT0N0 esophageal squamous cell carcinoma patients. *J Surg Oncol.* 106(4):436-40.
  45. Chao YK, Liu HP, **Chang HK** et al. (2012): Lymph node dissection after chemoradiation in esophageal cancer: a subgroup analysis of patients with and without pathological response. *Ann Surg Oncol.* 19(11):3500-5.